CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY
|
|
- Sophia Page
- 6 years ago
- Views:
Transcription
1 CARCINOMA OF UNKNOWN PRIMARY: DIAGNOSTIC APPROACH USING IMMUNOHISTOCHEMISTRY Jason L Hornick, MD, PhD Director of Surgical Pathology Director of Immunohistochemistry Brigham and Women s Hospital Associate Professor of Pathology Harvard Medical School Boston, MA, USA Carcinoma of unknown primary Definition: histologically confirmed metastatic carcinoma for which primary site cannot be identified after standard diagnostic approach: Detailed history and physical examination Blood counts and biochemical analysis Urinalysis and stool occult blood test CT of thorax, abdomen, and pelvis Histologic review including IHC Carcinoma of unknown primary Account for 2-5% of malignancies diagnosed in the US 7 th or 8 th most frequent cancer 4 th or 5 th most common cause of cancer death in both sexes 31,000 new cases in the US in 2012 down from 45,000 new cases in 1995 Improved radiologic imaging Increasingly specific IHC markers Page 1 1
2 Origin of primary tumors (autopsy) Organ Incidence Pancreas 20-25% Lung 15-20% Colon/rectum 5-10% Liver/biliary 5-10% Stomach 5% Kidney 5% Ovary <5% Prostate <5% Breast 2% Other 1% Histologic groups of carcinoma of unknown primary Histology Well or moderately differentiated adenocarcinoma Poorly differentiated adenocarcinoma or undifferentiated carcinoma Frequency 60% 30% Squamous cell carcinoma 5% Undifferentiated malignant neoplasm 5% Overview Distribution of keratin family members in carcinomas Lineage-restricted markers and primary site determination Primary tumors of the liver and mimics Squamous cell carcinomas Primary site determination for metastatic neuroendocrine tumors Page 2 2
3 Keratin family members in carcinomas Low-molecular-weight keratins (CK8, CK18, CAM5.2) Glandular epithelium, hepatocytes High-molecular-weight keratins (CK5, CK14, 34βE12) Squamous epithelium, urothelium, basal cells Keratin family members in carcinomas: CK7 and CK20 CK7 wide distribution in epithelial cells CK20 restricted to lower GI tract epithelium, umbrella cells of the urinary bladder, Merkel cells CK7 and CK20 are they (still) useful? Phenotype Primary sites CK7 / CK20+ Colon/rectum CK7+ / CK20+ Bladder, upper GI, pancreas CK7 / CK20 Uncommon (prostate, HCC) CK7+ / CK20 Nearly everything else Page 3 3
4 Metastatic colonic adenocarcinoma CK20 Metastatic colonic adenocarcinoma CK7 Metastatic colonic adenocarcinoma CK20 Page 4 4
5 IHC for lineage/site specification: cytoplasmic/membranous markers Primary site Bladder Breast Breast Colon/rectum Lung Prostate Prostate Thyroid Marker Uroplakin GCDFP-15 (prolactin-inducible protein) Mammaglobin (SCGB2A1/A2) Villin Napsin A Prostate-specific antigen Prostatic acid phosphatase Thyroglobulin IHC for lineage/site specification: cytoplasmic/membranous markers In general, expression is decreased (or entirely absent) with poor differentiation significant impact on sensitivity Breast carcinoma GCDFP Page 5 5
6 Breast carcinoma GCDFP Breast carcinoma mammaglobin Expression of mammaglobin in other tumor types Tumor type Endometrial endometrioid adenocarcinoma Frequency 20-40% Skin adnexal carcinomas 20-40% Salivary gland neoplasms 20-50% Page 6 6
7 Prostatic adenocarcinoma PSA Lung adenocarcinoma Napsin A Napsin A Warning: napsin A is also positive in most papillary renal cell carcinomas Page 7 7
8 IHC for lineage/site specification: nuclear transcription factors Insights gained from developmental and cell biology research Transcription factors involved in patterning of organ systems, lineage commitment Some are highly specific for particular cell type or visceral organ Others show expression limited to several tissue types Very helpful in determining primary site for CUP IHC for lineage/site specification: nuclear transcription factors 10 years ago, very few were used in surgical pathology practice TTF1, CDX2, MYOG In 2016, over 50 markers with potential diagnostic applications are available Carcinomas, lymphomas, melanoma, germ cell tumors, sarcomas IHC for lineage/site specification: nuclear transcription factors Transcription factor Primary site CDX2 GATA3 NKX3-1 OCT4 PAX8 SALL4 SATB2 SF1 TTF1 (NKX2-1) WT1 Colon/rectum, upper GI Breast, bladder Prostate Seminoma, embryonal carcinoma Thyroid, kidney, Müllerian Germ cell tumors Colon/rectum Adrenal cortex Lung, thyroid Müllerian, mesothelioma Page 8 8
9 IHC for lineage/site specification: nuclear transcription factors In general, even poorly differentiated carcinomas maintain (relatively) diffuse expression in most cases high sensitivity With increasing study, specificity decreases Beware of relying on a single diagnostic marker TTF1 (NKX2-1) Lineage-specific transcription factor long history of use in diagnostic IHC Originally named for role in activating transcription from thyroglobulin promoter Expressed in normal and neoplastic thyroid follicular cells Most widely used application: ascribing lung origin to primary and metastatic adenocarcinomas (and supporting adenocarcinoma over squamous cell carcinoma in poorly differentiated NSCLCA) Lung adenocarcinoma TTF1 Page 9 9
10 Metastatic poorly differentiated lung adenocarcinoma TTF1 Poorly differentiated (insular) thyroid carcinoma TTF1 TTF1 Warning: TTF1 is also positive in a subset of endometrial adenocarcinomas (most common in grade 3 endometrioid and serous) Some variation in sensitivity and specificity based on particular clone Page 10 10
11 Expression of TTF1 in carcinomas I Primary site Positive cases Pulmonary (adenocarcinoma) 70-90% Pulmonary (squamous cell carcinoma) <10% Thyroid (all types) % Cholangiocarcinoma (extrahepatic) 5-25%* Endometrial 5-20%* Ovarian 5-30%* *These cases usually show expression in only a small fraction of tumor cells. Expression of TTF1 in carcinomas II Primary site Positive cases Gastric/esophageal <10% Cervical <5% Pancreatic <5% Breast <5% Urothelial <5% Colorectal <5% Hepatocellular <5% Salivary gland (adenoid cystic) 30-50% Salivary gland (other) <5% Adrenal cortical <5% TTF1: potential diagnostic pitfall Cytoplasmic staining relatively common Diffuse staining in normal hepatocytes and many hepatocellular carcinomas Likely represents cross-reactivity with CPS1 (antigen recognized by HepPar-1 antibody) Subset of adenocarcinomas from various sites (especially foregut) also show cytoplasmic staining Page 11 11
12 Hepatocellular carcinoma TTF1 WT1 Wilms tumor 1 Transcription factor plays diverse roles in cancer depending upon tumor type and biological context Expressed in malignant mesothelioma, serous carcinoma Positive in nearly all serous carcinomas of the ovary; uncommon in serous carcinomas of the endometrium (variable results in different studies) Malignant mesothelioma WT1 Page 12 12
13 Metastatic mesothelioma WT1 Metastatic serous carcinoma WT1 WT1 Among carcinomas, nuclear WT1 relatively specific for ovarian serous tumors Positive in <5% of breast, lung, gastric, colorectal, urothelial carcinomas Cytoplasmic staining detected in subset of other carcinomas and various other tumor types only nuclear staining should be considered positive for ascribing site of origin Page 13 13
14 CDX2 Caudal-type homeobox transcription factor involved in intestinal differentiation Nuclear expression in >90% colorectal adenocarcinomas Somewhat lower sensitivity in high grade and MSI-H carcinomas Widely used to support colorectal origin No significant loss of sensitivity in the metastatic setting Colonic adenocarcinoma CDX2 Metastatic colonic adenocarcinoma CDX2 Page 14 14
15 CDX2 Also expressed in carcinomas from other gastrointestinal primary sites associated with intestinal differentiation Esophagus and stomach Pancreas and biliary tree Often more heterogeneous staining in tumors from these other sites Particularly helpful in differential diagnosis between primary (poorly cohesive) gastric carcinoma and metastatic breast carcinoma Gastric adenocarcinoma CDX2 CDX2 Warning: CDX2 can also be positive in mucinous adenocarcinomas from diverse anatomic sites Ovary Lung Pancreas Bladder Page 15 15
16 Expression of CDX2 in carcinomas Primary site Positive cases Colorectal and appendiceal % Gastroesophageal 40-60% Pancreatic/biliary 30-50% Ovarian (mucinous and endometrioid) 40-60% Ovarian (serous) <10% Endometrial 5-10% Pulmonary (mucinous) 70-80% Pulmonary (non-mucinous) <5% Bladder (adenocarcinoma) 30-50% Bladder (urothelial) <5% Prostatic <5% Breast <5% Renal <5% GATA3 Transcription factor originally recognized for role in T-cell function Clinically useful as marker for breast or urothelial origin Positive in >80% of breast and urothelial carcinomas No significant loss of sensitivity in the metastatic setting More recent large surveys revealed expression in wide range of tumor types Bladder urothelial carcinoma GATA3 Page 16 16
17 Bladder urothelial carcinoma GATA3 Breast carcinoma GATA3 Breast carcinoma GATA3 Page 17 17
18 Expression of GATA3 in other tumors Tumor type Frequency Squamous cell carcinoma (skin) 80% Squamous cell carcinoma (cervix) 33% Squamous cell carcinoma (lung) 10% Lung adenocarcinoma 5-10% Skin adnexal carcinomas % Mesothelioma 25-60% Salivary gland tumors 20-50% Pancreatic ductal adenocarcinoma 40% Paraganglioma 80% Choriocarcinoma 100% Chromophobe renal cell carcinoma 50% Potential value of GATA3 in differential diagnosis Positive Negative Metastatic lobular breast carcinoma Gastric signet-ring-cell carcinoma Metastaticductal breast carcinoma Urothelial carcinoma Squamous cell carcinoma of skin Malignantmesothelioma Paraganglioma Choriocarcinoma, yolk sac tumor Lung/GI/ovarianadenocarcinoma Prostatic adenocarcinoma Squamous cell carcinoma of lung Lung adenocarcinoma Other neuroendocrine tumors Embryonalcarcinoma, seminoma Am J Surg Pathol. 38:13-22, 2014 NKX3-1 Homeobox transcription factor, androgendependent Expression limited to prostate Usually more diffusely positive than conventional cytoplasmic markers Helpful to distinguish high grade prostatic adenocarcinoma from urothelial carcinoma Helpful to suggest prostatic origin in metastatic carcinoma Page 18 18
19 Prostatic adenocarcinoma NKX3-1 Expression of NKX3-1 in carcinomas Primary site Positive cases Prostatic % Breast (lobular) 15-30% Breast (ductal) <10% Bladder (urothelial and adenocarcinoma) <5% Pancreatic/biliary <5% Hepatocellular <5% Renal <5% Colorectal <5% Gastroesophageal <5% Pulmonary <5% Thyroid <5% SATB2 More recently described transcription factor expressed in colorectal/appendiceal epithelium Similarly high sensitivity and likely higher specificity than CDX2 Positive in 80-90% of primary and metastatic colorectal adenocarcinomas Higher sensitivity than CDX2 for medullary carcinomas Unlike CDX2, SATB2 rarely expressed in gastroesophageal and pancreaticobiliary adenocarcinomas Page 19 19
20 Colonic adenocarcinoma SATB2 Poorly differentiated colonic adenocarcinoma SATB2 Expression of SATB2 in carcinomas Primary site Positive cases Colorectal and appendiceal % Renal 25-35% Gastroesophageal 10-20%* Pancreatic/biliary 10-20%* Mullerian 10-20%* Pulmonary 10-20%* Bladder (urothelial) 10-20%* Prostatic 5-15%* Breast 5-15%* Thyroid <5%* *These cases show expression in only a small fraction of tumor cells. Page 20 20
21 PAX8 One of the most widely used lineagespecific transcription factors in IHC approach to CUP Highly sensitive for carcinomas originating in ovary, kidney, thyroid >90% serous, endometrioid, and clear cell ovarian carcinomas positive for PAX8 Much lower rate of expression in ovarian mucinous adenocarcinomas PAX2 largely supplanted by PAX8 Expression of PAX8 in carcinomas I Primary site Positive cases Renal 85-95% Thyroid (papillary, follicular, poorly diff) % Thyroid (anaplastic, medullary) 60-80% Ovarian (non-mucinous) % Ovarian (mucinous) 10-40% Endometrial % Cervical % Renal cell carcinoma PAX8 Page 21 21
22 Ovarian clear cell carcinoma PAX8 Metastatic serous carcinoma PAX8 Metastatic serous carcinoma PAX8 Page 22 22
23 Metastatic serous carcinoma TTF1 Papillary thyroid carcinoma PAX8 Poorly differentiated thyroid carcinoma TTF1 PAX8 Page 23 23
24 Metastatic lung adenocarcinoma TTF1 PAX8 Pan-PAX? Widely used polyclonal anti-pax8 antibody not specific for PAX8 Cross-reacts with other PAX family members (PAX5, PAX6, PAX3) Responsible for staining in B lymphocytes (PAX5) Responsible for staining in pancreatic well-differentiated neuroendocrine tumors (PAX6) PAX8-specific monoclonal antibodies available PAX8 PAX5 PAX6 Page 24 24
25 Expression of PAX8 in carcinomas II Primary site Positive cases Thymic (polyclonal antibody) 80-90% Pancreatic/biliary 5-10% Bladder (urothelial) 10-20% Gastric/esophageal 5-10% Colorectal/appendiceal <5% Hepatocellular <5% Breast <5% Pulmonary (adenocarcinoma) <5% Pulmonary (squamous cell carcinoma) 0-30% Head and neck (squamous cell carcinoma) <5% Adrenal cortical <5% Skin (squamous cell carcinoma) <5% SF1 Steroidogenic factor 1 (NR5A1) Recently investigated transcription factor Highly sensitive marker for sex cordstromal tumor Highly sensitive marker for adrenal cortical carcinoma Particularly useful in distinguishing primary adrenal cortical carcinoma from metastatic renal cell carcinoma Adrenal cortical carcinoma SF1 Page 25 25
26 ER and PR In addition to role as predictive biomarkers in breast cancer, can be useful to ascribe primary site in certain contexts Hormone receptor-positive breast carcinomas retain expression in metastatic foci in >90% of cases Most useful in patients with known history of hormone receptor-positive breast cancer and other known or suspected malignancies ER and PR Also commonly expressed in primary carcinomas of gynecologic tract Most ovarian serous carcinomas express ER Can be helpful to distinguish serous from clear cell carcinoma ER and PR ER consistently negative in colorectal, gastroesophageal, hepatocellular, pancreatic/biliary carcinomas ER positive (generally weak/focal) in small subset of lung adenocarcinomas PR less specific: positive in 30% of cholangiocarcinomas; positive in small subset of gastroesophageal, pancreatic, hepatocellular carcinomas Page 26 26
27 Embryonic stem cell transcription factors Transcription factors involved in maintenance of pluripotency Large body of literature on role in embryonic stem cell biology Some of these transcription factors useful in diagnostic IHC OCT4 (also known as OCT3/4) widely used in clinical practice Other markers less often used Expression of embryonic stem cell transcription factors in germ cell tumors Subtype SALL4 OCT4 NANOG SOX2 Seminoma Embryonal carcinoma Yolk sac tumor ++++ Teratoma ++ Choriocarcinoma variable Seminoma OCT4 Page 27 27
28 Don t forget to consider a primary liver tumor! Hepatocellular carcinoma Alpha fetoprotein (AFP) Low sensitivity Polyclonal carcinoembryonic antigen (CEA) Bile canalicular pattern Carbamoyl-phosphate synthase 1 (CPS1) = Hep-Par 1 antibody Urea cycle enzyme Also expressed in 5-10% of adenocarcinomas of diverse sites Arginase 1 (ARG1) Urea cycle enzyme Appears to be most sensitive and specific Hepatocellular carcinoma pcea Page 28 28
29 Hepatocellular carcinoma CPS1/Hep-Par1 Hepatocellular carcinoma ARG1 Potential mimics of HCC Adrenal cortical carcinoma Inhibin Melan-A/MART1 (MLANA) A103 >> M2-7C10 SF1 (steroidogenic factor 1; NR5A1) Renal cell carcinoma RCC (renal cell carcinoma marker) low sensitivity in the metastatic setting PAX2 less sensitive than PAX8 PAX8 highly sensitive marker, also positive in thyroid and Müllerian carcinomas Poorly differentiated cholangiocarcinoma Page 29 29
30 Adrenal cortical carcinoma SF1 Metastatic renal cell carcinoma RCC Metastatic renal cell carcinoma PAX8 Page 30 30
31 Intrahepatic cholangiocarcinoma Radiologic features: Large solitary mass +/- satellite lesions Biliary dilatation Hepatic capsular retraction Delayed enhancement Lobar/segmental atrophy Histology/immunophenotype essentially indistinguishable from pancreatic ductal adenocarcinoma CK7/CK19 positive Loss of SMAD4 (~50%) When you encounter a CK7+ AdCA in the liver, consider cholangiocarcinoma Intrahepatic cholangiocarcinoma Capsular retraction Biliary dilatation Satellite Intrahepatic cholangiocarcinoma Satellite Capsular retraction Page 31 31
32 Intrahepatic cholangiocarcinoma Intrahepatic cholangiocarcinoma Pancreatic ductal carcinoma SMAD4 Page 32 32
33 Metastatic cholangiocarcinoma SMAD4 Adenosquamous carcinoma SMAD4 Squamous cell carcinoma: P63 and P40 Confirmation relatively straightforward P63 (also positive in urothelial and subset of adenocarcinomas; ~20% lung AdCA) P40 (much more specific for squamous cell and urothelial carcinomas) In general, IHC not helpful to determine primary site (other than P16: HPVassociated SCC of oropharynx, cervix, anal canal) In situ hybridization can be helpful (head and neck): EBER nasopharyngeal carcinoma High-risk HPV oropharyngeal carcinomas (tonsil, base of tongue) Page 33 33
34 Lung squamous cell carcinoma P40 Metastatic HPV-associated squamous cell carcinoma P16 Well-differentiated neuroendocrine tumors 10-20% of NET present as metastasis of unknown primary Midgut (ileum) >> pancreas >> other Determination of primary site increasingly important for well-differentiated NET Recent introduction of effective systemic therapies Different efficacies for midgut vs pancreatic origin Page 34 34
35 Systemic therapy for metastatic welldifferentiated neuroendocrine tumors Agent Mechanism Efficacy Midgut Pancreas Octreotide Somatostatin analogue + + Interferon-α Immune activation + + Streptozocin Alkylating agent + Temozolomide Alkylating agent + Everolimus mtor inhibitor +/ + Sunitinib Tyrosine kinase inhibitor + Bellizzi Adv Anat Pathol 2013 Transcription factor expression in welldifferentiated neuroendocrine tumors Transcription factor CDX2 ISL1 ppax8 PDX1 TTF1 Primary sites Midgut (ileum), appendix >> pancreas Pancreas Pancreas, duodenum, rectum Pancreas, duodenum Lung Transcription factor expression in welldifferentiated neuroendocrine tumors Transcription factor CDX2 ISL1 ppax8 PDX1 TTF1 Primary sites Midgut (ileum), appendix >> pancreas Pancreas Pancreas, duodenum, rectum Pancreas, duodenum Lung Page 35 35
36 CDX2 expression in well-differentiated neuroendocrine tumors Primary site Positive Lung <5% Stomach 15-30% Duodenum 30-45% Pancreas 15-20% Jejunum/ileum 90% Appendix 90% Rectum 0-30% CDX2 expression in well-differentiated neuroendocrine tumors Primary site Positive Lung <5% Stomach 15-30% Duodenum 30-45% Pancreas 15-20% Jejunum/ileum 90% Appendix 90% Rectum 0-30% Metastatic well-differentiated neuroendocrine tumor from ileum CDX2 Page 36 36
37 Metastatic well-differentiated neuroendocrine tumor from pancreas CDX2 Polyclonal PAX8 expression in welldifferentiated neuroendocrine tumors Primary site Positive Lung 0-10% Stomach 15% Duodenum 80% Pancreas 55-70% Jejunum/ileum 0% Appendix 15% Rectum 60% Polyclonal PAX8 expression in welldifferentiated neuroendocrine tumors Primary site Positive Lung 0-10% Stomach 15% Duodenum 80% Pancreas 55-70% Jejunum/ileum 0% Appendix 15% Rectum 60% Page 37 37
38 Pancreatic well-differentiated neuroendocrine tumor ppax8 Metastatic well-differentiated neuroendocrine tumor from ileum ppax8 Polyclonal PAX8 antibody PAX8 PAX6 PAX5 Page 38 38
39 Pancreatic well-differentiated neuroendocrine tumor PAX6 PDX1 Pancreatic and duodenal homeobox transcription factor Also known as insulin promoter factor 1 Necessary for pancreatic development Plays role in maturation of islet cells that secrete insulin (β-cells) and somatostatin (δ-cells) In adult pancreas, strong nuclear expression in islet cells, weak staining in centroacinar cells PDX1 expression in well-differentiated neuroendocrine tumors Primary site Positive Lung 0-5% Stomach 60% Duodenum 60% Pancreas 55-80% Jejunum/ileum 0% Appendix 40% Rectum 15% Page 39 39
40 PDX1 expression in well-differentiated neuroendocrine tumors Primary site Positive Lung 0-5% Stomach 60% Duodenum 60% Pancreas 55-80% Jejunum/ileum 0% Appendix 40% Rectum 15% Metastatic pancreatic well-differentiated neuroendocrine tumor PDX1 ISL1 ISLET1 Transcription factor with N-terminal LIM domains and C-terminal homeodomain Plays critical role in develop of pancreatic islets of Langerhans In adults, strong nuclear expression in islets Clinically used antibodies show cytoplasmic staining in perivascular smooth muscle Page 40 40
41 ISL1 expression in well-differentiated neuroendocrine tumors Primary site Positive Lung 10-15% Stomach 0% Duodenum 90% Pancreas 70-85% Jejunum/ileum <5% Appendix 15-20% Rectum 90% ISL1 expression in well-differentiated neuroendocrine tumors Primary site Positive Lung 10-15% Stomach 0% Duodenum 90% Pancreas 70-85% Jejunum/ileum <5% Appendix 15-20% Rectum 90% Pancreas ISL1 Page 41 41
42 Pancreatic well-differentiated neuroendocrine tumor ISL1 Metastatic well-differentiated neuroendocrine tumor from ileum ISL1 Small cell carcinoma Determination of primary site not important All patients treated with cisplatin/carboplatin + etoposide Localized Merkel cell carcinoma treated surgically TTF1 is not specific for lung in this setting TTF1 positive in >90% of small cell carcinoma of lung TTF1 positive in 30-50% of extrapulmonary small cell carcinoma TTF1 rarely positive in Merkel cell carcinoma Page 42 42
43 Metastatic small cell carcinoma TTF1 Other transcription factors in small cell carcinoma Small cell carcinomas show marked transcription factor lineage infidelity! Common to detect expression of 5-10 (or more) different transcription factors in both pulmonary and extrapulmonary small cell carcinomas Important to be aware of this phenomenon to avoid misinterpretation Transcription factor expression in small cell and Merkel cell carcinomas Courtesy of Dr. Andrew Bellizzi Page 43 43
44 Practice points Review radiologic findings (could the biopsy be from a primary liver tumor?) Pay close attention to histologic features Guide judicious panel of IHC markers Increasing range of antibodies directed against transcription factors becoming available Be aware of reported cross-reactivity (i.e., specificity) to avoid misdiagnosis Page 44 44
Carcinoma of Unknown Primary (CUP)
Metasta c Carcinoma of Unknown Primary: Diagnos c Approach Using Immunohistochemistry James R. Conner, MD, PhD Mount Sinai Hospital Toronto, ON Carcinoma of Unknown Primary (CUP) 3-5% of all new malignant
More informationCarcinoma of unknown primary origin (CUP) is defined
REVIEW ARTICLE Metastatic Carcinoma of Unknown Primary: Diagnostic Approach Using Immunohistochemistry James R. Conner, MD, PhD and Jason L. Hornick, MD, PhD Abstract: Carcinoma of unknown primary origin
More informationThe clinically challenging entity of liver metastasis from tumors of unknown primary
The clinically challenging entity of liver metastasis from tumors of unknown primary Xuchen Zhang, MD, PhD Associate Professor of Pathology Department of Pathology Yale University School of Medicine Liver
More informationThe Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationDifferential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
More informationBreast cancer: IHC classification. Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
Breast cancer: IHC classification Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark http://upload.wikimedia.org/wikipedia/commons/1/1a/breast.svg
More informationReporting of carcinoma of unknown primary tumour (CUP)
Reporting of carcinoma of unknown primary tumour (CUP) Prof John Schofield Kent Oncology Centre with grateful thanks to Dr Karin Oien University of Glasgow Royal College of Pathologists Cancer datasets
More informationHistopathological diagnosis of CUP
Histopathological diagnosis of CUP Dr Karin Oien karin.oien@glasgow.ac.uk Disclosure slide Dr Karin Oien has no financial interests in any company mentioned in this presentation. Dr Karin Oien is conducting
More informationCutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology
Cutaneous metastases Thaddeus Mully University of California, San Francisco Professor, Departments of Pathology and Dermatology DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY Thaddeus Mully Course C005 Essential
More informationNEW IHC A n t i b o d i e s
NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology
More informationNordic Immunohistochemical Quality Control
Nordic Immunohistochemical Quality Control Immunohistochemistry in the classifiation of neoplasias of the alimentary tract & External Quality Assurance of Immunohistochemistry for GI cancer markers Mogens
More informationThe unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part II)
The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
More informationNew Developments in Immunohistochemistry for Gynecologic Pathology
New Developments in Immunohistochemistry for Gynecologic Pathology Michael T. Deavers, M.D. Professor, Departments of Pathology and Gynecologic Oncology Immunohistochemistry in Gynecologic Pathology Majority
More informationLiver Specialty Evening Conference. Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle
Liver Specialty Evening Conference Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle Case History A 65 year-old man presents with abdominal
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationDiagnostic IHC in lung and pleura pathology
Diagnostic IHC in lung and pleura pathology Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark WHO 2004 and Web Malignant mesothelioma Epithelioid
More informationHow to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html
More information8 years later! Next Generation Sequencing. Pathogenic Findings: HNF1A c.864delinscc, p.g292rfs*25 (NM_ ) (VAF: 59%) HNF1A Loss
8 years later! Next Generation Sequencing Pathogenic Findings: HNF1A c.864delinscc, p.g292rfs*25 (NM_000545.6) (VAF: 59%) HNF1A Loss Interpretation HNF1A c.864delinscc, p.g292rfs*25 (NM_000545.6) This
More informationList of Available TMAs in the PRN
TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2
More informationBreast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases
Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2
More informationTumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.
Tumour Markers What are Tumour Markers? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer
More informationAdnexal primary or Melanocy+c prolifera+ons in sundamaged metastatic carcinoma?
Adnexal primary or Melanocy+c prolifera+ons in sundamaged metastatic carcinoma? skin Jane L. Messina, MD Interna0onal Melanoma Pathology Working Group 4 th annual mee0ng Tampa, Florida November 14, 2011
More informationImmunohistochemical classification of lung carcinomas and mesotheliomas. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark
Immunohistochemical classification of lung carcinomas and mesotheliomas Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Endobronchial ultrasound guided transbronchial needle biopsy
More informationSupplementary Online Content
Supplementary Online Content Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the
More informationA 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy.
November 2015 Case of the Month A 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy. Contributed by: Rasha Salama, M.D., IU Department of Pathology and Laboratory Medicine
More informationThe role of immunohistochemistry in surgical pathology of the uterine corpus and cervix
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1 trials currently open for patients with pheochromocytoma and/or paraganglima (from trials.gov) www.clinicaltrials.gov; Active PPGL trials Status Of Sunitinib In Patients With Recurrent
More informationSection 14 Other Cancers. Cancer of Unknown 113 Primary Site INTRODUCTION PATHOLOGIC EVALUATION
Section 14 Other Cancers Cancer of Unknown 113 Primary Site F. Anthony Greco and John D. Hainsworth INTRODUCTION Cancer of unknown primary (CUP) site is a clinical syndrome that includes many types of
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More informationISSN X (Print) Original Research Article. DOI: /sjams
DOI: 10.21276/sjams.2016.4.7.33 Scholars Journal of Applied Medical Sciences (SJAMS) Sch. J. App. Med. Sci., 2016; 4(7C):2468-2473 Scholars Academic and Scientific Publisher (An International Publisher
More informationExpression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases
Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Peiguo G. Chu, M.D., Ph.D., Lawrence M. Weiss, M.D. Department of Pathology, City of Hope National Medical Center,
More informationWhat I Learned from 3 Cases and 3 Antibodies
What I Learned from 3 Cases and 3 Antibodies Melinda Sanders, M.D Vanderbilt University Medical Center Professor of Pathology Consultant in Breast Pathology Disclosure of Relevant Financial Relationships
More informationMalignant neoplasms of the gastrointestinal (GI) tract,
Special Section First Chinese American Pathologists Association Diagnostic Pathology Course, Part II Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary
More informationFNA Cytology of Metastatic Malignancies of Unknown Primary Site
FNA Cytology of Metastatic Malignancies of Unknown Primary Site Tarik M. Elsheikh Jan F. Silverman Pathologic Diagnosis of Metastasis Smaller specimens, less invasive techniques FNA cytology is highly
More informationSHN-1 Human Digestive Panel Test results
SHN-1 Human Digestive Panel Test results HN-30 tongue HN-24 salivary gland HN-12 larynx HN-28 esophagus HN-29 stomach HN-20 pancreas HN-13 liver HN-14 gall bladder HN-27-1 duodenum HN-27-2 ileum HN-27-3
More informationincidence rate x 100,000/year
Tier R=rare C=common Cancer Entity European crude and age adjusted incidence by cancer, years of diagnosis 2000 and 2007 Analisys based on 83 population-based cancer registries * applying the European
More informationPathology Mystery and Surprise
Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor
More information4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD
MUSC Pathology Symposium Kiawah Island April 18, 2018 Jesse K. McKenney, MD 1 Urothelial Carcinoma with Alternative Differentiation 2 Urothelial Carcinoma with Alternative Differentiation Recognition as
More informationNICHOLAS PAVLIDIS, MD, PhD, FRCP (Edin)
CANCER OF UNKNOWN PRIMARY A Complex Disease NICHOLAS PAVLIDIS, MD, PhD, FRCP (Edin) PROFESSOR OF MEDICAL ONCOLOGY Bogota, May-June 2016 WHAT IS CANCER OF UNKNOWN PRIMARY (CUP)? Is a clinical disorder where
More informationICD-O Morphology code. R=Rare Tier Tumour ICD-O Topography code C30.0, C31
R=Rare Tier Tumour ICD-O Topography code ICD-O Morphology code EPITHELIAL TUMOURS OF NASAL CAVITY AND SINUSES R 2 Squamous cell carcinoma with variants of nasal cavity and sinuses C30.0, C3 C30.0, C3 8000,
More informationOther Sites. Table 2 Continued. MPH Rules 11/8/07. NAACCR Webinar Series 1
MPH s 11/8/07 Other s 1 Table 2 Continued Use this two-page table to select combination histology codes. Compare the terms in the diagnosis to the terms in Columns 1 and 2. If the terms match, code the
More informationCase 18. M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is:
Case 18 M75. Excision of mass on scalp. Clinically SCC. The best diagnosis is: A. Pilomatrical carcinoma B. Adnexal carcinoma NOS C. Metastatic squamous cell carcinoma D.Primary squamous cell carcinoma
More informationCase Hx. Mrs. CP 69 female non smoker Presented with 20 lb weight loss Some changes in bowel habit but no bleeding Upper abdominal discomfort PMH
Case Hx Mrs. CP 69 female non smoker Presented with 20 lb weight loss Some changes in bowel habit but no bleeding Upper abdominal discomfort PMH HTN, Dyslipidemia, GERD Breast reduction surgery Surgeries
More informationNeuroendocrine Carcinoma. Lebanon Neuroendocrine Neoplasms of H&N Nov /7/2011. Broad Classification:
H&N Neuroendocrine Neoplasms: Classification and Diagnostic Considerations Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Broad Classification: A. Epithelial:
More informationClassification of the unknown primary tumour: the primary IHC panel
CIQC/CAP-ACP SEMINAR 2013: DIAGNOSTIC IHC AND MOLECULAR PATHOLOGY Classification of the unknown primary tumour: the primary IHC panel Aalborg University Hospital Denmark Tumours of unknown origin: Histology
More informationINTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS. Gabor Fischer Diagnostic Services Manitoba University of Manitoba
INTERPRETATION OF IMMUNOHISTOCHEMICAL STAINS - DIFFICULTIES AND PITFALLS Gabor Fischer Diagnostic Services Manitoba University of Manitoba IHC INTERPRETATIONS LOCAL DATA Diagnostic Services Manitoba Number
More informationImmunohistochemical classification of the unknown primary tumour (UPT) Part I. Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark
Immunohistochemical classification of the unknown primary tumour (UPT) Part I Prof. Mogens Vyberg NordiQC Institute of Pathology Aalborg, Denmark Tumours of unknown origin: Histology Brain tumour - biopsy
More informationIHC Panels as an Aid in Diagnostic Decision Making
IHC Antibody Test Selection Using a Panel Approach Steven Westra B.S. Reagent Product Specialist Leica Biosystems IHC Panels as an Aid in Diagnostic Decision Making Diagnostic Use of Tumors Using Algorithms
More informationInterventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies
Web appendix 2: SEARCH STRATEGIES Interventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies MEDLINE 1. exp epidemiologic studies/
More informationCODING TUMOUR MORPHOLOGY. Otto Visser
CODING TUMOUR MORPHOLOGY Otto Visser INTRODUCTION The morphology describes the tissue of the tumour closest to normal tissue Well differentiated tumours are closest to normal Undifferentiated tumours show
More informationTechnology from Abcam
CD2 (EP222) CD2 is one of the earliest T-cell lineage restricted antigens to appear during T-cell differentiation and only rare CD2+ cells can be found in the bone marrow. Anti-CD2 is a pan-t-cell antigen
More informationEnterprise Interest Nothing to declare
Enterprise Interest Nothing to declare Update of mixed tumours of the GI tract, the pancreas and the liver Introduction to the concept of mixed tumours and clinical implication Jean-Yves SCOAZEC Surgical
More informationWendy L Frankel. Chair and Distinguished Professor
1 Wendy L Frankel Chair and Distinguished Professor Case 1 59 y/o woman Abdominal pain No personal or family history of cancer History of colon polyps Colonoscopy Polypoid rectosigmoid mass Biopsy 3 4
More informationVideo Microscopy Tutorial 8
Video Microscopy Tutorial 8 Common and Uncommon Lesions of the Liver Gladwyn Leiman, MD There are no disclosures necessary. Common and Uncommon Lesions in Liver FNA Gladwyn Leiman University of Vermont
More informationNICHOLAS PAVLIDIS, MD, PhD, FRCP (Edin)
CANCER OF UNKNOWN PRIMARY A Complex Disease NICHOLAS PAVLIDIS, MD, PhD, FRCP (Edin) EMERITUS PROFESSOR, UNIVERSITY OF IOANNINA DEAN, MEDICAL SCHOOL, UNIVERSITY OF CYPRUS ESO / ESMO MASTERCLASS, SAN JOSE,
More informationMEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site
POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization
More information3/28/2017. Disclosure of Relevant Financial Relationships. Clinical History. Pathology
Disclosure of Relevant Financial Relationships Monalisa Sur MBBS, FCPath(S.A), MMED(WITS), FRCPath(U.K), FRCP( C) Professor, Department of Pathology and Molecular Medicine Division of Anatomical Pathology
More informationFNA Cytology of Metastatic Malignancies of Unknown Primary Site
FNA Cytology of Metastatic Malignancies of Unknown Primary Site Tarik M. Elsheikh Cleveland Clinic Jan F. Silverman Alleghany Hospitals Pathologic Diagnosis of Metastasis Smaller specimens, less invasive
More informationCASE 4 21/07/2017. Ectopic Prostatic Tissue in Cervix. Female 31. LLETZ for borderline nuclear abnormalities
Female 31 CASE 4 LLETZ for borderline nuclear abnormalities PSA Ectopic Prostatic Tissue in Cervix AJSP 2006;30;209-215 usually incidental microscopic finding usually in ectocervical stroma? developmental
More informationEffusion Cytology: Diagnostic Challenges
Effusion Cytology: Diagnostic Challenges Tarik M. Elsheikh, MD Professor and Medical Director, Anatomic Pathology Cleveland Clinic Outside Consult Case 45 year old woman, presented with nausea, dyspnea,
More informationOberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide)
GEP-NET Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) 1 Histogenesis 16 different
More informationImmunohistochemistry and Bladder Tumours
Immunohistochemistry and Bladder Tumours Dr. Andrew J. Evans MD PhD FRCPC Consultant in Genitourinary Pathology University Health Network Toronto, ON Objec ves Review markers of urothelial differen a on
More informationMody. AIS vs. Invasive Adenocarcinoma of the Cervix
Common Problems in Gynecologic Pathology Michael T. Deavers, M.D. Houston Methodist Hospital, Houston, Texas Common Problems in Gynecologic Pathology Adenocarcinoma in-situ (AIS) of the Cervix vs. Invasive
More informationPATOLOGIA MOLECULAR DEL CANCER DE ORIGEN DESCONOCIDO? Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.
PATOLOGIA MOLECULAR DEL CANCER DE ORIGEN DESCONOCIDO? Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA. CANCER UNKNOWN PRIMARY 3-5 % of diagnosed cancers Variability
More informationCharles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources
Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources 1 IHC Identification Targets Specimens Controls 2 Tissue controls Trouble Spots 3 The Key to Description IHC Description 4 Intermediate Filaments
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationDATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
More informationTissue-Specific Cadherin CDH17 Is a Useful Marker of Gastrointestinal Adenocarcinomas With Higher Sensitivity Than CDX2
Anatomic Pathology / CDH17 in Gastrointestinal Carcinomas Tissue-Specific Cadherin CDH17 Is a Useful Marker of Gastrointestinal Adenocarcinomas With Higher Sensitivity Than CDX2 Nicole C. Panarelli, MD,
More informationHOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT 2011
HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT 2011 SONGKLANAGARIND HOSPITAL FACULTY OF MEDICINE PRINCE OF SONGKLA UNIVERSITY HATYAI SONGKHLA THAILAND EDITOR PARADEE PRECHAWITTAYAKUL, B.Sc. June, 2013 Songklanagarind
More informationReview and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors
Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors. Monophasic tumors : myoepithelioma, acinic cell carcinoma, and salivary duct carcinoma. Biphasic tumors includes
More informationCoordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma
Anatomic Pathology / CYTOKERATINS 7 AND 20 IN PROSTATE AND BLADDER CARCINOMAS Coordinate Expression of Cytokeratins 7 and 20 in Prostate Adenocarcinoma and Bladder Urothelial Carcinoma Nader H. Bassily,
More informationTissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review
Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: a Systematic Review Sandra Lee MD, FRCPC 1 *, Vikrant V. Sahasrabuddhe, MBBS, DrPH 2 *, Diana
More informationPresentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
More informationImportancia del patólogo en los tumores de origen desconocido
Importancia del patólogo en los tumores de origen desconocido Dr. Federico Rojo Fundación Jiménez Díaz, Madrid IMIM-Hospital del Mar, Barcelona Cancer unknown primary 3-5 % of diagnosed cancers Variability
More informationIntrahepatic cholangiocarcinoma Histologic spectrum, novel markers and molecular assays
2018 Current Issues in Surgical Pathology Summary (not actual lecture) Intrahepatic cholangiocarcinoma Histologic spectrum, novel markers and molecular assays Sanjay Kakar, MD University of California,
More informationWT1, Estrogen Receptor, and Progesterone Receptor as Markers for Breast or Ovarian Primary Sites in Metastatic Adenocarcinoma to Body Fluids
Anatomic Pathology / WT1, ESTROGEN RECEPTOR, AND PROGESTERONE RECEPTOR IN CYTOLOGY OF BODY FLUIDS WT1, Estrogen Receptor, and Progesterone Receptor as Markers for Breast or Ovarian Primary Sites in Metastatic
More informationSingle and Multiplex Immunohistochemistry
Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch
More informationAdenocarcinoma of the Cervix
Question 1. Each of the following statements about cervical adenocarcinoma is true except: Adenocarcinoma of the Cervix SAMS a) A majority of women with cervical adenocarcinoma have stage I tumors at diagnosis.
More informationThe European Commission s science and knowledge service. Joint Research Centre
The European Commission s science and knowledge service Joint Research Centre Coding Primary Site and Tumour Morphology JRC-ENCR training course Copenhagen, 25 September 2018 Nadya Dimitrova Outline What
More informationWhen Immunostains Can Get You in Trouble: Gynecologic Pathology p16: Panacea or Pandora s Box?
When Immunostains Can Get You in Trouble: Gynecologic Pathology p16: Panacea or Pandora s Box? Teri A. Longacre, MD Stanford Medicine Stanford California pi6 in Gynecologic Pathology: Panacea or Pandora
More informationThe unkown primary tumour: IHC Classification, antibody selection, protocol optimization, controls and EQA (part I)
The unkown primary tumour: IHC Classification, antibody selection, protocol optimization, Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark
More informationTumor Markers & Cytopathology
Tumor Markers & Cytopathology Objectives: After learning, student should be able to 1. Describe the basic concepts of tumor markers and Asst. Prof. Prasit Suwannalert, Ph.D. (Email: prasit.suw@mahidol.ac.th)
More informationTumor Immunology. Tumor (latin) = swelling
Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to
More informationCEA (CARCINOEMBRYONIC ANTIGEN)
(CARCINOEMBRYONIC ANTIGEN) 428 C15.3 Malignant neoplasm of upper third of esophagus C15.4 Malignant neoplasm of middle third of esophagus C15.5 Malignant neoplasm of lower third of esophagus C15.8 Malignant
More informationRadiology Pathology Conference
Radiology Pathology Conference Nadia F. Yusaf, M.D. PGY-3 1/29/2010 Presentation material is for education purposes only. All rights reserved. 2010 URMC Radiology Page 1 of 90 Case 1 60 year- old man presents
More informationMolecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology
DOI:10.1093/jnci/djt099 Article JNCI Journal of the National Cancer Institute Advance Access published May 2, 2013 The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions,
More informationBEST PRACTICES IN THE APPLICATION OF IMMUNOHISTOCHEMISTRY TO DIAGNOSTIC UROLOGIC PATHOLOGY: LESSONS FROM USES & ABUSES
BEST PRACTICES IN THE APPLICATION OF IMMUNOHISTOCHEMISTRY TO DIAGNOSTIC UROLOGIC PATHOLOGY: LESSONS FROM USES & ABUSES Mahul B. Amin Professor & Chairman Department of Pathology & Laboratory Medicine Cedars-Sinai
More information2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
More informationTUMOR M ARKERS MARKERS
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
More informationAppendix 4: WHO Classification of Tumours of the pancreas 17
S3.01 The WHO histological tumour type must be recorded. CS3.01a The histological type of the tumour should be recorded based on the current WHO classification 17 (refer to Appendices 4-7). Appendix 4:
More informationCHAPTER 137 CANCER OF UNKNOWN PRIMARY SITE
SECTION 14: OTHER CANCERS F. ANTHONY GRECO AND JOHN D. HAINSWORTH CHAPTER 137 CANCER OF UNKNOWN PRIMARY SITE Cancer of unknown primary (CUP) site is a clinical syndrome that represents many types of cancers.
More informationSerous effusion Objectives. Cytology of Serous Effusions From basics to challenges
Cytology of Serous Effusions From basics to challenges Cytology of Serous Effusions From basics to challenges Pınar Fırat, MD, MIAC Department of Pathology, İstanbul University, İstanbul Faculty of Medicine,
More informationTEST MENU BY SPECIALTY
1 TEST MENU BY SPECIALTY Breast Pathology Surgical excisions, needle core biopsies, and plastic surgery accepted from all sites Assessment of margins Axillary lymph node dissections Sentinel lymph nodes
More informationMT09 - Normal Human Tissue Microarray, FDA
Reveal Biosciences offers Histochemical Staining, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Whole Slide Imaging, and Quantitative Image Analysis on any TMA MT09 - Normal Human Tissue Microarray,
More informationOvarian Clear Cell Carcinoma
Ovarian Clear Cell Carcinoma Rouba Ali-Fehmi, MD Professor of Pathology The Karmanos Cancer Institute, Wayne State University School of Medicine 50 year old woman with chief complaint of shortness of breath
More informationRenal tumours: use of immunohistochemistry & molecular pathology. Dr Lisa Browning John Radcliffe Hospital Oxford
Renal tumours: use of immunohistochemistry & molecular pathology Dr Lisa Browning John Radcliffe Hospital Oxford Renal tumours: the use of immunohistochemistry & molecular pathology Classification of RCC
More informationTesticular Germ Cell Tumors; A Simplistic Approach
Testicular Germ Cell Tumors; A Simplistic Approach Merce Jorda, MD, PhD, MBA Professor and Vice Chair, Director of Anatomic Pathology Director of Genitourinary Pathology Service Interim Director of Cytopathology
More information